Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090669 · ClinicalTrials.gov registry record · Phase 1
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
A Phase 1 study of Inherited Bone Marrow Failure Syndrome and Familial Platelet Disorder With Predisposition to Myeloid Malignancies, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06090669: Recruiting Phase 1 study of Inherited Bone Marrow Failure Syndrome and Familial Platelet Disorder With Predisposition to Myeloid Malignancies, sponsored by National Cancer Institute (NCI).
NCT06090669 is a Phase 1 study of Inherited Bone Marrow Failure Syndrome and Familial Platelet Disorder With Predisposition to Myeloid Malignancies that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 75 participants, below the 746-participant average among 3 other Inherited Bone Marrow Failure Syndrome trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06090669, a Phase 1 study of Inherited Bone Marrow Failure Syndrome and Familial Platelet Disorder With Predisposition to Myeloid Malignancies, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Runt-related transcription factor 1 (RUNX1) gene regulates the formation of blood cells. People with mutations of this gene may bleed or bruise easily; they are also at higher risk of getting cancers of the blood, bone marrow, and lymph nodes. Objective: The purpose of the study includes determining which dose of imatinib is best for people with pathogenic or likely pathogenic RUNX1 mutations without blood cancers, and to determine whether there are any changes in platelet function and inflammatory markers. Eligibility: Adults aged 18 and older with RUNX1 mutations. Healthy people without this mutation, including family members of affected participants, are also needed. Design: Participants with the RUNX1 mutation will be screened. They will have a physical exam with blood tests. They will have a test of their heart function. They may need a new bone marrow biopsy if they haven't had one in the past year. Imatinib is a tablet taken by mouth once a day, every day, at home. Affected participants in different parts of the study will take imatinib for either 28 days or up to 84 days. They will fill out questionnaires about how they are feeling. For the first part of the study, participants will have blood tests every 2 weeks, either at home or at the NIH, while they are taking the imatinib. They will have a follow up visit, at home or at the NIH, when they are done taking imatinib on Day 28. Participants on the second part of the study will come to NIH on days 1 and days 84. They will have blood tests every 2 weeks (at home or the NIH) while they are taking imatinib. They may opt to have a bone marrow biopsy repeated after they finish their course of imatinib. Participants will have a follow-up visit (at home or the NIH) 30 days after they stop taking imatinib. Participants who do not have the RUNX1 mutation will have 1 clinic visit. They will have blood tests. They will fill out questionnaires. They may opt to have a bone marrow biopsy.
Primary Outcome
Safety will be evaluated by the number of DLTs identified at each dose level. The number of DLTs at each dose level will be reported and used to determine the RP2D.
Conditions Studied
Interventions
- DRUG imatinib
- DEVICE TruSight Oncology
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2027-10-30 |
| Phase | Phase 1 |
What NCT06090669 shows while recruiting
NCT06090669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 746-participant average among 3 other Inherited Bone Marrow Failure Syndrome trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Inherited Bone Marrow Failure Syndrome appearing as the primary indexed condition, and to 2 interventions - of which imatinib is the first listed.
NCT06090669 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06090669 about?
NCT06090669 is a clinical study titled "Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency". Background: Runt-related transcription factor 1 (RUNX1) gene regulates the formation of blood cells. People with mutations of this gene may bleed or bruise easily; they are also at higher risk of getting cancers of the blood, bone marrow, and lymph nodes. Objective: The purpose of the study inclu...
What is the current status of trial NCT06090669?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2023-12-19. Estimated completion is 2027-10-30.
What conditions does trial NCT06090669 study?
This clinical trial studies the following conditions: Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies.
What interventions are being tested in trial NCT06090669?
The interventions under investigation include: imatinib (DRUG), TruSight Oncology (DEVICE).
Who is sponsoring clinical trial NCT06090669?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06090669 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inherited Bone Marrow Failure Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
RECRUITING
-
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI